Clinical trial
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison…
NCT00434967 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00434967 |
|---|---|
| Title | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo |
| Official title | A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Candesartan cilexetil, Hydrochlorothiazide, Candesartan/HCT 32/25 mg |
| Enrollment | 2,207 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Feb 14, 2007 |
| Last update posted | Dec 16, 2010 |
| Countries | Belgium, Latvia, Malta, Romania, Russia, Slovakia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: